title: New drugs for ovarian cancer.
authors.affiliation: Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill College of Medicine, Cornell University, 1275 York Avenue, New York, NY 10065, USA.
authors.forename: K
authors.initials: K
authors.lastname: Bell-McGuinn
authors.forename: J
authors.initials: J
authors.lastname: Konner
authors.forename: W
authors.initials: W
authors.lastname: Tew
authors.forename: D R
authors.initials: DR
authors.lastname: Spriggs
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors